2-chlorodeoxyadenosine — Competitive Intelligence Brief

2-chlorodeoxyadenosine (2-chlorodeoxyadenosine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: purine nucleoside analog. Area: Oncology.

phase 2 purine nucleoside analog DNA Oncology Small molecule

Target snapshot

2-chlorodeoxyadenosine (2-chlorodeoxyadenosine) — North American Consortium for Histiocytosis. 2-chlorodeoxyadenosine is a purine nucleoside analog that inhibits DNA synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
2-chlorodeoxyadenosine TARGET	2-chlorodeoxyadenosine	North American Consortium for Histiocytosis	phase 2	purine nucleoside analog	DNA
CEDAZURIDINE	CEDAZURIDINE		marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA methyltransferase	2020-01-01
Dacogen	decitabine	Sun Pharma	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2006-01-01
Vidaza	azacitidine	Bristol-Myers Squibb	marketed	Nucleoside Metabolic Inhibitor [EPC]	DNA (cytosine-5)-methyltransferase 1	2004-01-01
Zymar	GATIFLOXACIN	Allergan	marketed		DNA gyrase, DNA gyrase, DNA gyrase subunit A	2003-01-01
Eloxatin	Oxaliplatin	Yakult Honsha	marketed	Platinum-based chemotherapy agent	DNA	2002-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

• 2029-05-14 — Vidaza · 12053482 · Method of Use · US
• 2029-05-14 — Vidaza · 11571436 · Formulation · US
• 2030-06-03 — Vidaza · 8846628 · Formulation · US

Sponsor landscape (purine nucleoside analog class)

1. North American Consortium for Histiocytosis · 1 drug in this class